Vivos Therapeutics (VVOS) AI Stock Analysis

• Market Cap: $14.16M
• Dividend Yield: N/A
• Average Volume (3M): 421.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: 18.76%
• EPS Growth: 60.09%
• Country: US
• Employees: 109
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.49
• Shares Outstanding: 9,437,788
• 10 Day Avg. Volume: 324,525
• 30 Day Avg. Volume: 421,860
• PEG Ratio: 0.02
• Price to Book (P/B): 2.71
• Price to Sales (P/S): 1.43
• P/FCF Ratio: -1.62
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 0.57
• Enterprise Value/Gross Profit: 1.02
• Enterprise Value/Ebitda: -0.62
• 1Y Price Target: $5.00
• Price Target Upside: 125.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $1.50 ▼(-32.43% Downside)

The score is held down primarily by weak financial performance (persistent losses, worsening cash burn, and a more pressured balance sheet) and bearish technical signals (price below key moving averages with negative MACD). Offsetting factors include strong recent revenue growth and a strategic pivot highlighted on the earnings call, but ongoing cost escalation and the need for bridge/equity financing keep risk elevated, while valuation offers limited support due to negative earnings and no dividend.

Positive Factors

Revenue Momentum

Sustained revenue acceleration from the acquisition-led strategy demonstrates real demand traction and a scalable growth vector. The 76% Q3 jump reflects expanding service and treatment volumes that can compound over quarters as the company integrates centers and leverages referrals, improving fixed-cost absorption and long-term revenue base.

Healthy Gross Margins

Consistently mid-50s gross margins indicate attractive unit economics for Vivos' non-surgical OSA treatment and service mix. With scale from acquisitions and treatment center growth, these margins provide room for operating leverage: higher revenue should drive outsized improvements in operating profitability if SG&A growth is controlled.

Strategic Acquisition Model & Conversion

The shift to acquiring/affiliating sleep practices creates a repeatable distribution channel and accelerates patient conversion into Vivos treatments. High conversion rates and meaningful case economics (> $5k) support predictable service revenue and unit profitability, enabling faster geographic scale and tighter control over patient experience and clinical protocols.

Negative Factors

Persistent Cash Burn

Chronic negative operating and free cash flow near -$14.4M TTM creates an ongoing funding requirement and heightens dilution and refinancing risk. Without a clear path to sustained positive cash generation, the company must rely on external capital to support operations and acquisitions, limiting strategic flexibility over the medium term.

Thin Equity / Rising Leverage

A thin equity cushion and higher leverage reduce balance-sheet resilience to shocks and constrain the company's ability to fund growth or absorb integration costs. Limited shareholder equity increases the probability that future financing will be dilutive or restrictive, raising execution risk for the acquisition-driven strategy.

Rising Operating Costs

Sharp increases in G&A and other operating costs are outpacing early revenue gains, undermining margin sustainability. If cost growth continues with acquisitions and integration, it may delay breakeven and require deeper cuts or more capital, meaning management must demonstrate disciplined cost control alongside growth to realize long-term profitability.

Vivos Therapeutics Business Overview & Revenue Model

Company Description

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

How the Company Makes Money

Vivos Therapeutics generates revenue primarily through the sale of its patented medical devices and treatment systems for sleep apnea. The company operates a direct-to-consumer model as well as a business-to-business model, partnering with dental and healthcare professionals to promote and distribute its products. Key revenue streams include the sale of its oral appliances, ongoing treatment subscriptions, and potential licensing agreements. Vivos also benefits from collaborations with healthcare providers and institutions that utilize its technology in patient care, contributing to recurring revenue through follow-up treatments and related services.

Vivos Therapeutics Financial Statement Overview

Summary

Revenue is improving (TTM up ~20%) and gross margin is healthy (~56–60%), but the company remains deeply unprofitable with a larger TTM net loss (~$17.1M vs. ~$11.1M in 2024). Cash flow is persistently negative and worsening (TTM operating/FCF about -$14.4M), while equity has fallen sharply and leverage vs. equity has risen (D/E ~1.63), increasing financing risk.

Income Statement

Revenue has improved over time with solid momentum in TTM (Trailing-Twelve-Months) (up ~20%), following a modest increase in 2024 and a decline in 2023. However, profitability remains the core issue: gross margin is healthy (~56–60% recently), but operating and net margins are deeply negative, and TTM net loss (~$17.1M) is larger than 2024’s loss (~$11.1M). Overall, the business shows demand traction, but cost structure is still overwhelming the revenue base.

Balance Sheet

Leverage has moved in the wrong direction most recently: debt-to-equity rose to ~1.63 in TTM (Trailing-Twelve-Months) as equity fell sharply (to ~$2.5M from ~$8.0M in 2024), reducing balance-sheet flexibility. While total debt remains modest in dollars (~$4.1M TTM), the thin equity cushion elevates risk. Returns on equity are meaningfully negative across periods, reflecting ongoing losses and erosion of shareholder value.

Cash Flow

Cash generation is weak, with operating cash flow negative in every period shown and worsening to about -$14.4M in TTM (Trailing-Twelve-Months). Free cash flow is also consistently negative (about -$14.4M TTM) and has recently deteriorated, indicating continued cash burn to fund operations. While free cash flow broadly tracks net losses (i.e., losses are not being masked by non-cash accounting), the company still lacks a clear path to self-funding based on the current cash flow profile.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.32M	15.03M	13.80M	16.02M	16.89M	13.07M
Gross Profit	9.65M	9.02M	8.27M	10.02M	12.60M	10.41M
EBITDA	-15.97M	-10.55M	-16.68M	-24.36M	-19.54M	-11.24M
Net Income	-17.10M	-11.14M	-13.58M	-23.84M	-20.29M	-12.06M
Balance Sheet
Total Assets	25.64M	15.28M	10.73M	13.72M	33.69M	25.33M
Cash, Cash Equivalents and Short-Term Investments	3.09M	6.26M	1.64M	3.52M	24.03M	18.21M
Total Debt	4.12M	1.51M	2.00M	2.41M	1.63M	1.29M
Total Liabilities	23.11M	7.33M	10.32M	8.92M	8.15M	8.41M
Stockholders Equity	2.53M	7.95M	411.00K	4.80M	25.54M	16.92M
Cash Flow
Free Cash Flow	-14.43M	-13.26M	-12.75M	-20.51M	-18.13M	-5.80M
Operating Cash Flow	-14.39M	-12.69M	-11.95M	-19.59M	-15.73M	-5.68M
Investing Cash Flow	-6.11M	-568.00K	-853.00K	-924.00K	-2.61M	-120.25K
Financing Cash Flow	17.28M	17.88M	10.92M	0.00	24.17M	23.54M

Vivos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 2.22 is above the 20-day moving average (MA) of 1.87, above the 50-day MA of 2.02, and below the 200-day MA of 3.09, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 28.97 is Positive, neither overbought nor oversold. The STOCH value of 13.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.

Vivos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IRIX	46 Neutral	$24.75M	-4.76	-139.29%	―	4.58%	55.26%
CODX	44 Neutral	$4.92M	-0.08	-62.12%	―	-87.84%	29.16%
VVOS	43 Neutral	$14.16M	-0.76	-335.47%	―	18.76%	60.09%
ADGM	43 Neutral	$21.82M	-0.19	-210.36%	―	-70.54%	70.03%
COCH	42 Neutral	$16.64M	-0.43	―	―	-25.18%	-9.71%

Vivos Therapeutics Corporate Events

Vivos Therapeutics Completes Warrant Inducement Financing Transaction

On January 15, 2026, Vivos Therapeutics entered into a warrant inducement agreement with an institutional holder under which the investor agreed to exercise in full previously issued warrants from January 2023, November 2023 and February 2024 at a reduced exercise price of $2.34 per share, generating approximately $4.6 million in gross proceeds for the company. In return, Vivos issued new Series A and Series B inducement warrants for a total of 3,964,712 shares at $2.09 per share in a private placement, with the inducement transaction closing on January 20, 2026, subject to resale registration obligations, restrictions on new equity issuance and variable-rate financings, and customary protections in the warrants, while H.C. Wainwright received cash fees, expense reimbursements and additional warrants as compensation. The company plans to use the net proceeds for working capital and general corporate purposes, a move that bolsters its near-term liquidity but also adds potential future equity dilution for existing shareholders.

The most recent analyst rating on (VVOS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.

Vivos Therapeutics Secures Convertible Bridge Financing Facility

On January 15, 2026, Vivos Therapeutics, Inc. entered into an unsecured, non‑interest‑bearing (absent default) convertible promissory note of up to $5.5 million in maximum principal with V-Co Investors 3 LLC, an affiliate of existing private equity investor New Seneca Partners Inc., to provide bridge funding ahead of a proposed equity financing of the same size expected to close by February 16, 2026. The note, which includes a 10% original issuance discount as a financing fee, provided an initial $900,000 advance on January 15, 2026, will automatically convert dollar-for-dollar into the securities issued in the contemplated equity raise if that financing occurs before the outside date, and was placed as an unregistered private offering under U.S. securities law, underscoring Vivos’s near-term funding needs and further aligning the company with an existing strategic investor while diluting future equity rather than adding interest-bearing debt.

The most recent analyst rating on (VVOS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.

Vivos Therapeutics Secures $2M Note with Avondale

On December 5, 2025, Vivos Therapeutics, Inc. entered into a Note Purchase Agreement with Avondale Capital, LLC, resulting in a $2,093,340 promissory note. The company received approximately $1,500,000 in net proceeds, which it intends to use for working capital and general corporate purposes. The note, which is unsecured and non-convertible, includes an original issue discount and requires weekly payments. Vivos Therapeutics has also arranged for its subsidiary to guarantee the company’s obligations under the note. The agreement outlines customary events of default, such as nonpayment and bankruptcy, which could trigger interest accrual or immediate repayment.

The most recent analyst rating on (VVOS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.

Vivos Therapeutics Holds Annual Stockholders Meeting

On November 4, 2025, Vivos Therapeutics, Inc. held its annual meeting of stockholders, where key decisions were made regarding the company’s governance and strategic direction. The stockholders elected six directors to the board for a one-year term, approved an amendment to the 2024 Omnibus Equity Incentive Plan, and ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s operational strategies and financial oversight, reinforcing its governance structure and aligning its incentive plans with future growth objectives.

The most recent analyst rating on (VVOS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.